A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: First Affiliated Hospital Zhejiang University, Zhejiang University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University, Zhengzhou University, Henan Cancer Hospital, Shandong University, Qilu Hospital of Shandong University, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, China Medical University, Central South University, Xiangya Hospital Central South University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417002345
Cites:
Cited by:
Related to: